| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jean-Marc Tréluyer | Q41653833 |
| P2093 | author name string | Gérard Pons | |
| Jean-Marc Tréluyer | |||
| Agnès Tran | |||
| Elisabeth Rey | |||
| Frederike Lentz | |||
| P2860 | cites work | The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire | Q29615435 |
| Pharmacogenomics: translating functional genomics into rational therapeutics | Q33751829 | ||
| Gender differences in dopaminergic function in striatum and nucleus accumbens | Q33791869 | ||
| Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy | Q34207652 | ||
| In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography | Q34269010 | ||
| A comparison of sustained-release bupropion and placebo for smoking cessation | Q73804709 | ||
| Testing drug response in the presence of genetic information: sampling issues for clinical trials | Q74278928 | ||
| Cellular mechanisms of nicotine addiction | Q34498016 | ||
| Treatment non-adherence in affective disorders. | Q34592227 | ||
| Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. | Q34743847 | ||
| Biological basis of sex differences in drug abuse: preclinical and clinical studies | Q34982405 | ||
| Allelic association of human dopamine D2 receptor gene in alcoholism | Q34998499 | ||
| Nicotine as a modulator of behavior: beyond the inverted U. | Q35216455 | ||
| One year effectiveness of an individualised smoking cessation intervention at the workplace: a randomised controlled trial. | Q35498511 | ||
| Current pharmacological treatments for nicotine dependence | Q35629258 | ||
| The genetic basis for smoking behavior: a systematic review and meta-analysis | Q35888652 | ||
| Biochemical validation of smoking status: pros, cons, and data from four low-intensity intervention trials. | Q36762974 | ||
| Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. | Q40702716 | ||
| Effects of gender on relapse prevention in smokers treated with bupropion SR. | Q42675497 | ||
| Bupropion for smoking cessation : predictors of successful outcome | Q43604755 | ||
| Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender | Q43673470 | ||
| Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. | Q43700709 | ||
| Striatal dopamine transporters and cognitive functioning in healthy men and women | Q43726221 | ||
| Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. | Q43902574 | ||
| Nonadherence with mood stabilizers: prevalence and predictors | Q43999454 | ||
| Biochemical verification of tobacco use and cessation | Q44005083 | ||
| Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. | Q44185954 | ||
| Pharmacogenetic investigation of smoking cessation treatment | Q44221292 | ||
| Bupropion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed-care setting | Q44399831 | ||
| The need for dissemination of evidence-based results from research on nicotine and tobacco | Q44440058 | ||
| Comment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels". | Q44468790 | ||
| Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation | Q44611149 | ||
| Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial | Q44626401 | ||
| Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial | Q44633869 | ||
| Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome | Q44688205 | ||
| Heterogeneity in 12-month outcome among female and male smokers | Q44751527 | ||
| The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. | Q47634728 | ||
| DRD2 allele frequencies and linkage disequilibria, including the -141CIns/Del promoter polymorphism, in European-American, African-American, and Japanese subjects | Q47732174 | ||
| The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers | Q47806955 | ||
| Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers | Q48170316 | ||
| D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. | Q48563699 | ||
| Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population | Q48704774 | ||
| A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation | Q48770780 | ||
| Assessing linkage disequilibrium in a complex genetic system. I. Overall deviation from random association. | Q52080480 | ||
| DNA by mail: an inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations. | Q52194659 | ||
| Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. | Q52236611 | ||
| Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. | Q52275787 | ||
| Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis | Q69804457 | ||
| The validity of self-reported smoking: a review and meta-analysis | Q72029301 | ||
| Mutation detection by TaqMan-allele specific amplification: application to molecular diagnosis of glycogen storage disease type Ia and medium-chain acyl-CoA dehydrogenase deficiency | Q73389171 | ||
| Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking | Q73532004 | ||
| P433 | issue | 1 | |
| P921 | main subject | colorectal cancer | Q188874 |
| fluorouracil | Q238512 | ||
| irinotecan | Q412197 | ||
| oxaliplatin | Q422327 | ||
| pharmacogenomics | Q1152227 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 21-33 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Molecular Diagnosis and Therapy | Q15758832 |
| P1476 | title | Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications | |
| P478 | volume | 5 |
| Q36927570 | A genome-wide screen for nicotine dependence susceptibility loci |
| Q39519836 | A prospective study of the effects of the DRD2/ANKK1 TaqIA polymorphism and impulsivity on smoking initiation. |
| Q24186545 | Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation |
| Q47882474 | Adherence to pharmacological smoking cessation interventions: A literature review and synthesis of correlates and barriers |
| Q24201167 | Antidepressants for smoking cessation |
| Q24246426 | Antidepressants for smoking cessation |
| Q28541543 | Applying of hierarchical clustering to analysis of protein patterns in the human cancer-associated liver |
| Q38044592 | Association between dopamine receptor 2 TaqIA polymorphisms and smoking behavior with an influence of ethnicity: a systematic review and meta-analysis update |
| Q34504968 | Asthma discordance in twins is linked to epigenetic modifications of T cells |
| Q24202466 | Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation |
| Q51980372 | C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency. |
| Q57380880 | Can pharmacogenetics help smokers quit? |
| Q37623502 | Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases |
| Q24186008 | Combined pharmacotherapy and behavioural interventions for smoking cessation |
| Q24198116 | Combined pharmacotherapy and behavioural interventions for smoking cessation |
| Q30435362 | Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation |
| Q34145173 | Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care |
| Q36580581 | Current and emerging pharmacotherapies for treating tobacco dependence |
| Q35012940 | Deciphering cellular states of innate tumor drug responses. |
| Q36511661 | Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. |
| Q41855504 | Effect of Uncaria tomentosa Extract on Apoptosis Triggered by Oxaliplatin Exposure on HT29 Cells. |
| Q57380847 | Effects of dopamine D2 receptor gene polymorphisms on smoking cessation: abstinence and withdrawal symptoms |
| Q36082618 | Gender Considerations in Addiction: Implications for Treatment |
| Q36837410 | Genetic influences on delay discounting in smokers: examination of a priori candidates and exploration of dopamine-related haplotypes |
| Q84049825 | Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer |
| Q36528263 | Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch |
| Q37264547 | Genetic variation in the dopamine pathway and smoking cessation |
| Q42936469 | Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. |
| Q37127185 | Identification of pharmacogenetic markers in smoking cessation therapy |
| Q90627232 | Identification of slit3 as a locus affecting nicotine preference in zebrafish and human smoking behaviour |
| Q46886425 | Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. |
| Q24203883 | Interventions for preventing weight gain after smoking cessation |
| Q36821781 | KCNN Genes that Encode Small-Conductance Ca2+-Activated K+ Channels Influence Alcohol and Drug Addiction. |
| Q36708951 | Overview of the pharmacogenomics of cigarette smoking |
| Q36192658 | Pharmacogenetics and nicotine addiction treatment |
| Q37848476 | Pharmacogenetics of alcohol, nicotine and drug addiction treatments |
| Q34132214 | Pharmacogenetics of nicotine addiction: role of dopamine |
| Q48015634 | Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. |
| Q43115874 | Prospective association of dopamine-related polymorphisms with smoking cessation in general care |
| Q22242313 | Smoke, Smoke, Smoke That Cigarette |
| Q52295623 | The potential of pharmacogenomics to treat drug addiction. |
| Q37371779 | Tobacco addiction and pharmacogenetics of nicotine metabolism |
| Q36451754 | Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer |
Search more.